The Medical Innovation Bill

A lot has been happening in terms of research policy at the moment, from the announcement of the European adaptive licensing pilot to the Government’s Early Access to Medicines scheme. The newest addition is the Medical Innovation Bill. But, what does this Bill mean? How is it different to the other initiatives and why are we not supporting it?

What’s the difference?

The idea of adaptive licensing is that medicines should be licensed for use in patients more quickly. The Early Access to Medicines scheme announced earlier this month is run by the Government and, in principle, hopes to speed up the process by making drugs available several years before they are licensed. The net result should be much the same – earlier access to promising new drugs – but the UK scheme is already operational and should start having an effect more quickly.Read More »

Early Access to Medicines scheme

Last month the UK Government’s Department of Health announced an Early Access to Medicines Scheme. But, what is this new scheme? and what does it mean for people living with MND?

The drug trial processpipette

The only proven drug to slow progression in MND is riluzole. This is the only drug that has passed all the stages of drug testing – known as clinical trials – and has been shown to be beneficial for people living with MND. Clinical trials are the ‘gold standard’ and are put in place to ensure that a drug is safe and beneficial before it is given to patients.

Read More »